Satellos Bioscience Inc. MSLE
8.70
(0.01)
(0.11%)
as of 25 Sep
- Market cap
- $184.8M
- P/E
- 0.0×
Follow MSLE
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
10.68 | 15.48 | 6.84 | 9.94 | |
Current Ratio |
11.22 | 16.48 | 7.77 | 10.70 | |
Net Debt/EBITDA |
5.08 | 6.96 | 3.62 | 5.80 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.69 | 0.98 | 0.99 | 0.71 | |
Capex/Depreciation |
0.00 | (4.00) | 0.00 | (1.00) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.39) | (0.52) | (0.50) | (0.30) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.39) | (0.52) | (0.50) | (0.30) | |
Cash per Share |
2.97 | 3.79 | 1.90 | 2.48 | |
Shareholders Equity per Share |
2.88 | 3.83 | 1.90 | 2.44 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.88 | 3.83 | 1.90 | 2.44 | |
Free Cash Flow |
(8.03) | (9.59) | (7.26) | (4.13) | |
Working Capital |
59.90 | 70.66 | 27.78 | 33.99 | |
Capital Expenditures |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Current Asset Value |
59.90 | 70.66 | 27.78 | 33.99 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
| Other line items | |||||
Average Receivables |
0.48 | 0.53 | 0.40 | 0.17 | |
Average Payables |
4.32 | 3.63 | 3.84 | 3.08 | |
Average Assets |
53.44 | 59.80 | 41.32 | 27.62 | |
Average Common Equity |
49.13 | 56.17 | 37.47 | 24.55 |
Columns are period end dates